BIOFLOW-III UK Satellite Registry Orsiro Stent System

Launched by BIOTRONIK UK LTD. · Oct 2, 2014

Keywords

ClinConnect Summary

For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to long-term complications range from rather immediate elastic coil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to 50%. Such rates of recurrence have serious economic consequ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Symptomatic coronary artery disease
• • Subject signed informed consent for data release
• • Subject is geographically stable and willing to participate at all follow up assessments
• • Subject is ≥ 18 years of age
• Exclusion Criteria:
• • Subject did not sign informed consent for data release
• • Pregnancy
• • Known intolerance to aspirin, clopidogrel, Ticlopidine, heparin or any other anticoagulant/antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media
• • Planned surgery within 6 months after PCI unless dual antiplatelet therapy will be maintained
• • Currently participating in another study and primary endpoint not reached yet